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Abstract
Background Considerable time and energy are expended in
the scientific community to discuss the validity, importance,
and applicability of the results of clinical trials. Depending
on the goals, perspectives, and other motivating factors,
protagonists and skeptics come to different conclusions,
even when using the same methods and tools for critical
appraisal. The aim of this study was to complement existing
methods and tools with minor modifications to provide a
prototype instrument that generates commonly accepted
versions of critical appraisals.
Methods As a pilot experiment, one university-based and one
industry-based referee independently completed the twin
assessment of five trials published in well-recognized jour-
nals. They identified the study questions, defined the simplest,
i.e., ideal, study designs to answer these questions, and
checked eight validity criteria. Identical positive or negative
answers of both referees increased or decreased the validity
score. A maximum of two disagreements (0 score) was
allowed. This procedure, which had been tested by two
referees in a pilot experiment, was repeated with 19 third-year
medical students and their supervisor at the Universidade
Federal Fluminense, Niterói/RJ, Brasil. Four students each
played the roles of the industry-based and university-based
referees and finally recorded their consensus.
Results The two referees of the pilot experiment agreed in
all but one answer to the five investigated publications. The
points of criticism differed in various papers. The consen-
sus reached by the students considerably differed from the
consensus reached by the referees.
Conclusions A consensus score generated by two referees or
by two groups of students is feasible, but the achieved result is
not necessarily reproducible. The critical appraisal of the
study question in connection with the applied study design
deserves special attention. It is time consuming but possible to
identify and describe the possible flaws in the design conduct
and report of clinical trials, but it is unlikely to reach a
reproducible interpretation. These data indicate the problems
with even evidence-based assessments and appraisals: the
assessments may well be reproducible, but not the appraisals.
Quality scores that include also the appraisal may therefore be
interpreted with caution. Appraisals or quality scores may be
used for interim decisions until data are available that confirm
under real-world conditions what was predicted by the results
generated under ideal but artificial conditions of a clinical trial.
Keywords Assessment . Critical appraisal . Validity .
Consensus . Confirmation-based health care
Introduction
Jørgensen et al. (2006) are probably correct in their
conclusions in a recent article that “industry-supported
Members of SHUFFLE (Students Help Universidade Fedeal
Fluminense in Literature Export) are Prof. Dr.Tania G. Thomaz, MD,
Ian C.B.O. Costa (manager), Priscila F. de Amorim, Rafael C.
Astorga, Renato C. Branco, Igor Brandão, Gustavo M. Cardoso, Lara
Dan, Carolina D.Gonçalves, Thiago Gonçalves, Tabata Graciolli, Davi
L.Grilo, Ingrid E. Hinden, Pedro M.Lisboa, Gabriela M. Machado,
Pascale G. Massena, Lauanny A. Pereira, Rafael Perez, Natalia C.Z.
Silva, and Fábio J.S. Souza.
F. Porzsolt (*)




I. C. B. d. O. Costa : T. G. Thomaz
SHUFFLE, Dept Physiology, Federal University Fluminense,
Niterói, Rio de Janeiro, Brasil
e . osta : . . ho az
J Public Health (2009) 17:425–432
DOI 10.1007/s10389-009-0283-4
reviews of drugs should be read with caution, as they were
less transparent, had few reservations about methodological
limitations of the included trials, and had more favorable
conclusions than the corresponding Cochrane reviews”
(Jørgensen 2006). We are not sure that colleagues who work
in fundamental research and patient care—and write the
above-mentioned articles—behave with greater integrity than
colleagues in industry, but we are confident that they have
different interests and are motivated by different incentives.
The real problem is that these scientists and practicing
physicians in the public sector and those engaged in industry
are not the only stakeholders in the health-care system.
Hospital managers, network managers, and health insurers
also have slightly different perspectives and interests. Many
people realize the problem, but are reluctant to articulate it.
Therefore, Jørgensen’s statement has to be supplemented by
a second statement indicating that publications are one way
of ‘opinion framing’ influencing opinions, but there are
many other ways to influence health-care decisions.
Falsehoods may result from corrupted evidence or
corrupted dissemination of otherwise valid evidence. These
falsehoods, when consumed as truth by unwitting and well-
intentioned practitioners of EBM, then disseminated and
adopted as routine practice, may well result not only in
inappropriate quality standards and processes in health care,
but also in harm to patients. For example, the practicing
radiologist today knows that earlier diagnosis of lung cancer
can be achieved. The medical practitioner also is confident
that intervention after early diagnosis is more effective in
preventing death in this otherwise fatal disease. The practi-
tioner is thus inclined to consider such screening in a high-risk
person with suitably long life expectancy, especially when
asked to provide it. Official recommendations against lung-
cancer screening, said to be based on demonstrated lack of
effectiveness of traditional radiographic screening, create a
dilemma for the critically thinking practitioner who suspects
that something may be seriously wrong. What constitutes
evidence? Is it official recommendations or the practitioner’s
practical experience? Miettinen (Miettinen 2001) finally
concludes, "Tomorrow’s radiologists will need to be critical
thinkers, learning how to read books and journals and to
listen to ‘experts’ more skeptically". This opinion was
confirmed by the actual discussion about screening for
prostate cancer (Barry 2009). There is probably no other
way to acquire personal competence and comprehend what
is presented in the scientific literature. It is necessary to
understand that informed consent means sharing uncertainty
with patients; type-I error means avoiding false optimism,
and the intention-to-treat principle is nothing other than a
pragmatic analysis (van Gikn 1999). Whether intended or
not, omissions and misinterpretations are not conducive to
good medical practice and can harm patients and produce an
unnecessary financial burden on the health-care system.
Although there are about 40 scoring tools to assess the
quality of health information, there is no commonly accepted
standard tool (Darmoni 2001) and the validity of checklists is
rather low (Forestier 2005). One of the best elaborated
instruments is that of the Oxford Center of Evidence-Based
Medicine (Phillips). We compared this instrument with even
more complex instruments used by the National Institute of
Clinical Excellence (NICE) and the German Institute
(DIMDI) for appraising health technology assessment
(HTA) reports. Our study made two important observations.
Despite measuring different things, both instruments recog-
nized the serious weakness of the appraised key publications.
Second, despite the weakness mentioned in the core parts of
the HTA reports, which are read by scientists, the authors of
both reports recommended the use of the procedure in the
summaries of their HTA reports, which are read by policy
makers (Porzsolt 2005). This asymmetric distribution of
information generates problems.
Other examples demonstrate that even Cochrane reviews
are not free of weaknesses. We critically appraised the quality
of homeopathic studies that were included in a Cochrane
review and concluded that the quality of about half of the
included studies deserved the lowest validity score of 5 or 6 on
a scale of 1-6 (Nothardt 2007). We were also not satisfied
with the conclusion in our Cochrane review on the effect of
interferon in advanced renal-cell carcinoma (Coppin 2003)
and published a different interpretation in the same book
together with the same co-authors, but different auspices
(Porzsolt et al., 2003a, b). These three little stories
demonstrate that two scientists who use the same instrument
for assessment of the same study will not necessarily come
to the same conclusion. As a consequence there is an urgent
need to develop a standard method for evaluating scientific
evidence that can detect most of the common biases
(Darmoni 2001). In this paper we test an instrument designed
to help resolve reviewers’ disagreements.
Method
The scoring system
According to the EBM working group (Straus 2005) the
assessment of validity of a paper starts with the identifica-
tion of the investigated scientific question.
At this stage of assessment, we request to define the
most simple, i.e., the ideal study design that will answer the
study question. Second, this ideal study design is compared
with the actually applied design in the investigated study.
Third, two referees (one expected pro-advocate and one
expected contra-advocate) have to complete independently
the twin assessment by answering the same questions and
subsequently try to form a consensus.
426 J Public Health (2009) 17:425–432
If both referees agree with their answers one point will
be added to the score for each positive answer but one point
will be deducted for each negative answer. If the answers of
the two referees differ, scoring points will neither be added
nor deducted (zero points). As the uncertainty of the
assessment increases with increasing numbers of unclear
answers, we accept only results up to two disagreements. If
the two referees disagree in more than two answers, a third
independent referee should be included. As the assessment
includes eight questions (Table 1), a maximum of eight
points can be added or deducted from the initial score. To
avoid negative scores or a score of zero points, we start
with an initial score of nine points.
The interpretation of scores
Based on the described rule a maximum of 17 points and a
minimum of 1 point can be reached. Table 2 shows all
possible combinations. The gray area in Table 2 indicates
that this result is acceptable without including a third referee.
The validity of a paper can be then classified in five
categories: scores of 17 to 15 points indicate optimal validity,
scores of 14 to 12 points indicate good validity, scores of 11
to 9 points indicate fair validity, scores of 8 to 6 points
indicate borderline validity and fewer than 6 points indicate
insufficient validity. For example, assuming two referees
agree with a positive answer to four questions, with a
negative answer to three questions, and disagree with the
answer to one question, the total score will be 10. A score of
10 points classifies the validity of the assessed paper as ‘fair.’
Reproducibility of the scores
In order to test the reproducibility of the scores, the critical
appraisal completed by an industry-based and a university-
based referee was repeated by 20 medical students. In order
to reduce the workload for the students, each student had to
read two papers, one playing the role of a pro-advocate and
the other playing the role of the contra-advocate. Four
students each played the role of the pro- and four the role of
the contra-advocate. These eight students tried to find a
consensus applying the above-described instrument and
rules to each of the five analyzed papers.
Results
Validation of the chosen scoring system
To start with the validation process of the chosen scoring
system, we used papers that were proposed by the initiators
of previous EBHC courses. The EBHC students had to rate
the validity of these publications which are used to support
clinical guidelines. The five included studies were pub-
lished in Cancer (Dautzenberg 1999), The Lancet (Mehta
2001), The Lancet (Heart protection Study Collaborative
Group 2002), New England Journal of Medicine (Meunier
2004 and Piccard-Gebhardt 2005). Initially we planned to
use the published articles to demonstrate the difficulties of
bias detection without disclosing the publications. As a
result of a controversial and critical discussion, we felt we
had to disclose the full references and to offer everyone the
possibility to respond to our appraisal.
All of these publications described randomized con-
trolled trials and were probably rated as level-I evidence
according to the Oxford Centre for Evidence-based Med-
icine Levels of Evidence (Phillips). The results of our
evaluations provided by the referees and by the medical
students are shown in Table 3.
The two referees, a pharmacist employed by a pharma-
ceutical company and a internist (F.P.) working as clinical
Table 1 Scoring system for the Twin Assessment of Clinical Trials
(TACT)
No. Question Score§
-02 Compare ideal with actually applied study design –
-01 Classify as ‘potentially valid’/‘not valid’ if the 2




00 If potentially valid, start out with a score of 9 points 09
01 Add/deduct 1 point if the two study designs are
similar/different
02 Add/deduct 1 point if the risk profiles** of the
compared study populations are similar/different
03 Add/deduct 1 point if the allocation of patients to
the study groups was concealed/known to the
therapist
04 Add/deduct 1 point if doctors and patients were
continuously blinded/were not or not
continuously blinded during the entire
duration of the study
05 Add/deduct 1 point if the follow-up was long
enough/too short to detect the study endpoints
in most of the included patients
06 Add/deduct 1 point if all/not all included patients
were included in the calculation of the study
results
07 Add/deduct 1 point if all/not all included
patients were evaluated according to the
intent-to-treat principle
08 Add/deduct 1 point if adequate/inadequate
statistics were applied
Total score
§ A score of “0” indicates that there was no agreement among the two
referees in this point. *To classify a study design as potentially valid,
it has to be similar to the ‘ideal study design.’ Otherwise, the reasons
for not applying the ideal study design have to be presented. **If one
of the study groups has most of the described risks, even if the
difference is only minimal, the groups are not really comparable
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economist and employed by the university agreed with the
answers to each of the five papers, except for one point
(only one score “0”). It was not expected that the study
design would create the most serious problem. The referees
agreed in all five papers that the ideal study design was
different from the published study design. In three out of
five studies the masking (blinding) of the patients or the
intent-to-treat principle created a problem. The length of the
follow-up period was too short or the inclusion of all study
patients in the evaluation was incomplete in two out of the
five studies, and finally, the profiles of the compared study
populations or the concealment created a problem in two
studies. The statistics were adequate in all five studies.
In summary, this result suggested that the design of the
trials rather than the statistics may be problematic. Four out
of five randomized controlled trials received a score equal
to or more than 9, corresponding to a fair validity. The
referees marked one of the studies “borderline” with the
score of 8 points.
The students who had just completed a 1-week course on
Evidence-Based Health Care used the same procedure as
the referees for the critical appraisal of the five publications
and came to the following conclusions.
& A Controlled Study of Postoperative Radiotherapy for
Patients with Completely Resected Nonsmall Cell Lung
Carcinoma by Dautzenberg et al.
As the protocol was changed during the study, neither
the original study design nor the power calculation was still
be appropriate to answer the study question.
As the patients were aware of the assignment to the
treated or untreated group, the result of the study was
influenced by this information. The baseline risks were not
balanced. The higher risk in the radiotherapy group may
explain the higher mortality in this group. If the patients of
the control group did not really understand the informed
consent, a serious ethical and methodological problem has
to be considered as the results of this study were evaluated
Number of negative agreements of the two referees 
































5 14 13 12 11
4 13 12 11 10 09
3 12 11 10 09 08 07
2 11 10 09 08 07 06 05
1 10 09 08 07 06 05 04 03
0 09 08 07 06 05 04 03 02 01
Table 2 Score points as func-
tions of the numbers of positive
and negative agreements be-
tween referees. The grey fields
indicate results of assessments
in which both referees did not
disagree in more than two
answers. The validity can be
classified according to the num-
ber of score points in five
categories: 17-15 optimal; 14-12
good; 11-9 fair; 8-6 borderline;
<6 insufficient
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according to the intent-to-treat (ITT) principle. The appli-
cation of the ITT principle is not independent from the
patient’s informed consent: patients in the untreated group
may request the promising treatment and therefore reject
the random allocation or treated patients may not tolerate
the recommended treatment. Patients who are aware of the
experimental character of the offered treatment will more
frequently express their preference and have a higher
Table 3 Results of the referees’ and the students’ assessments. The
referees’ assessment was made by a pharmacist from a pharmaceutical
company and the FP. The second assessments were made by 20 medical
students. The publication was appraised by eight students (four pro-
advocates and four contra-advocates) who had to form a consensus. The
results demonstrate that the calculated scores may vary considerably
Question Dautzenberg et al.,
Cancer 1999





Meunier et al N
Engl J Med Meunier
et al., 2004
Piccard-Gebhardt N
Engl J Med 2005
Referees Students Referees Students Referees Students Referees Students Referees Students
If potentially valid
start out with a score
of 9 points
9 9 9 9 9 9 9 9 9 9
Add/deduct 1 point if
the two study designs
are similar/different




-1 +1 -1 +1
Add/deduct 1 point if




+1 -1 +1 +1 -1 +1 +1 +1 +1
Add/deduct 1 point if
the plan to allocate




+1 +1 +1 +1 +1 +1 0 -1 +1





entire period of the
study
-1 -1 +1 +1 -1 +1 +1 -1 -1
Add/deduct 1 point if
the follow up was
long enough/too
short to detect the
study endpoints in
most of the included
patients
+1 +1 -1 0 +1 +1 +1 -1 -1






+1 +1 -1 +1 +1 -1 -1 +1 -1






-1 -1 -1 -1 +1 -1 -1 0 +1




+1 +1 +1 +1 +1 +1 +1 +1 +1
Total score 11 11 9 12 11 <6 11 12 8 11
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chance of rejecting the offered treatment than patients who
are offered only one option (treatment or not treatment)
assuming that they are offered the best available standard.
Without clarification of this question, the data cannot be
interpreted. This is not only a theoretical consideration, the
practical importance has recently been discussed (Ohmann
2000). Some of us were not convinced that all patients were
really randomized as patients in worse conditions received
the more intensive treatment (radiotherapy).
& Effects of Pretreatment with Clopidogrel and Aspirin
Followed by Long-term Therapy in Patients Undergo-
ing Percutaneous Coronary Intervention: the PCI-
CURE Study by Metha et al.
We do not agree with the design. The study tried to
respond to two completely different questions in one trial.
The design is acceptable to test the effects of the first
30 days of treatment, but not the effects of long-term
treatment. On page 528 myocardial infarction was selected
as one outcome but was not routinely screened for. There
will be many undetected cases as well as cases that are
difficult to assess as positive or negative. One of the take
home messages to many participants of our group was the
impression that this treatment was recommended for more
than 1 year without presenting supportive data. The
appropriate follow-up period depends on the peak of
incidence of events, which is not mentioned in the article.
& MRC/BHF Heart Protection Study of Cholesterol
Lowering with Simvastatin in 20,536 High-risk Indi-
viduals: A Randomised Placebo Controlled Trial by
MRC/BHF Heart Protection Study Collaborative Group
We could well understand the practical but not really the
scientific aim of this study. The rules for selecting and
managing the patients were too complicated to use the
same rules in a confirmatory study. Patients who responded
to placebo were excluded from the trial as well as patients
who presented no response to simvastatin. This shows a
higher response rate than would be observed in real-world
conditions (Knipschild 1991). After an intensive discus-
sion we concluded that the result generated in this study is
not relevant for decisions in day-to-day practice.
& The Effects of Strontium Ranelate on the Risk of
Vertebral Fracture in Women with Postmenopausal
Osteoporosis by Meunier et al.
It is not mentioned whether or not the randomization
plan was concealed. No objective methods were described
to assess vertebral fractures. The statistical analysis should
not be made by the supporting agency. The use of six
different tests enhances the risk to select retrospectively a
positive result just by chance. The “run-in-phase” or
“qualification period” was included. Knipschild et al.
(1991) described a list of almost ten effects that can be
achieved by introducing this qualification period. The
problem is that such instruments will be abused unless the
induced effects are carefully appraised.
& Trastuzumab after Adjuvant Chemotherapy in HER2-
Positive Breast Cancer by Piccart-Gebhardt et al.
Although most relapses at this stage of the disease are
expected after 18 to 24 months, the median follow-up was
only 12 month. There is a considerable risk that many patients
in the untreated group were lost. The corresponding informa-
tion is missing. It is a serious flaw not to report the results of
the third arm even though these patients had so far received
the same treatment as the patients in the second arm. One
possible reason not to report these results may a difference
between the expected and the observed results. It is surprising
that even in a paper published 1 year later, no results of the
third arm were reported.
As compared to the referees, the students tended to give
slightly higher (better) marks with the exception of the
Heart Protection Study. The students thought that this study
was seriously flawed by non-reproducible selection and
attrition of patients and can therefore not be condisidered as
valid information.
Discussion
The systematic assessment of the validity of clinical trials
described in this paper has been tested over several years in
our student courses. The formal use of the improved
method in five publications demonstrates that even so-
called level I/II evidence is not free from bias and mistakes.
The procedure is easy to apply and seems to be more
effective in detecting potential bias than existing instru-
ments (Forestier 2005).
The decision to accept or reject scientific information for
policy-making is usually dichotomous: a paper will either
be included in a meta-analysis or in a guideline or not.
Most scientists and journal editors are convinced that their
journals with a high impact factor are more likely to
publish level-I or -II articles than journals with low impact
factors (Obremskey 2005). This is actually true, but it is
also true that bias in journals with high impact factors is
more difficult to detect than bias and mistakes in journals
with low impact factors (Delgado Rodriguez 2001).
We hypothesized that the TACT scoring system provides
the possibility of “fine tuning” the validity of a clinical trial,
giving information that may directly influence clinical
decisions (Fig. 1). This figure describes that three criteria
should be considered when making clinical decisions: the
described efficiacy or effectiveness of the compared
interventions, the validity of the scientific report that
430 J Public Health (2009) 17:425–432
describes the comparison of the two interventions and the
costs of the compared interventions. The most difficult
problem is the critical appraisal of the validity of the report.
To underline the significance of the validity we included in
our study only papers from journals with a high impact
factor. The critical appraisal demonstrated that even these
papers are not free from bias.
From our EBHC courses we know that the assessment of
validity may vary considerably among different referees
especially when they come from different groups of
stakeholders. Doctors and colleagues from industry will
rather play the roles of pro-advocates, while statisticians
and epidemiologists will rather take the role of the contra-
advocate. These differences in ratings are often based on
different expectations and opinions and will arise whenever
decisions have to be made. In order to reach such
decisions–especially in the highly emotional field of health
care–compromises will be inevitable. With increasing
complexity these compromises become more difficult.
Therefore, it was our goal to design a system for assessment
of validity of scientific papers that catalyzes compromises
at a very basic stage where rather simple questions can be
discussed. The details of the validation process were based
on experience with many sophisticated dodges, gimmicks
and ploys that were introduced by innovative scientists to
avoid random effects. Unfortunately, these tricks frequently
induce bias. The only reason to propose our twin
assessment of clinical trials is to increase the chance that
users of the information can recognize bias.
Even recognized tools, such as the checklist based on
the CONSORT statement (Mills 2004), can only identify
but not exclude bias. The necessary generation of a formal
consensus score seems to be a possibility to disclose
controversial issues of referees with different backgrounds
and different goals. We demonstrated that two referees
with different expectations and goals may provide a
combined judgment. Other checklists like the CONSORT
statement (Knipschild 1991) and the GRADE system
(GRADE working group 2004) are more detailed than
our short system, but even these do not address the
problems that have to be solved for assessment of the
validity when referees with different perspectives are
involved.
Conclusion
The formal assessment of the validity of clinical trials using
structured techniques and the subsequent appraisal of the
assessed results is one side of the medal. The other side
refers to the reproducibility of the appraisal and of the final
decisions.
The results of our study raise the question on the
reliability of structured appraisals by single referees. Single
referees or readers of scientific articles have neither the time
required for a critical analysis nor do they usually have the
necessary experience nor the patience to do this work. Our
experiments suggest that group discussions are more
effective than assessments by single persons in detecting
flaws and bias of clinical trials. In our experiment two
referees considered the quality of the Heart Protection
Study as fair, while the group of eight students detected too
many weak points to consider this study as valid (Table 3).
We therefore favor the idea of establishing groups of
referees—students or researchers—rather than single
experts who are trained, motivated and experienced enough
to offer this service. A high quality appraisal may require
2-6 h work for a discussion group.
The problem of variability of critical appraisals can
be solved by data that confirm that the results generated
under ideal but artificial conditions of clinical trials can
be reproduced under real-world-conditions. Until these
data are available, decision makers (academic teachers,
policy makers) may use external services that provide
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Fig. 1 Decision aid for users of
scientific information. Clinical
decisions should depend not
only on the effectiveness and on
costs of an intervention, but
should also consider the validity
of the data (translated from
Porzsolt 2003b)
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